Cancer Risk Management

There are topics in medicine where the data evolve slowly and cautiously. And then there are topics where the data have been sitting, quite patiently, waiting for us to catch up. Hormone replacement therapy (HRT) after risk-reducing oophorectomy in BRCA mutation carriers falls squarely into the latter category. The evidence is not new. It is not particularly controversial. And yet, the clinical hesitation persists, and patients are being negatively impacted.